Global Glaucoma Therapeutics Devices Market Size (2026-2030)

In 2025, the AI Model Monitoring and Guardrails Market was valued at approximately USD 2.28 Billion. It is projected to grow at a CAGR of around 11.7% during the forecast period of 2026–2030, reaching an estimated USD 3.96 Billion by 2030.

The Global Glaucoma Therapeutics Devices Market is a set of medical devices that are aimed at decreasing the intraocular pressure level and regulating glaucoma advancement to maintain sight and restrict the irreversible damage of the optic nerves. It contains implantable drainage systems, minimally invasive surgical systems, laser-based treatment platforms, and associated procedural equipment that are employed in specialist eye care environments. Pharmaceutical therapies, diagnostic-only devices, routine ophthalmic consumables, and non-glaucoma surgical equipment are not a part of the market. The increasing burden of chronic eye disease, increased life expectancy, and the necessity of effective intervention in cases where medication is not sufficient to be effective are fundamentally connected to demand.

The market has evolved significantly over the past few years. There is a shift in clinical practice towards earlier intervention, less recovery, and procedures that can be accommodated in the models of outpatient care. This has raised the concern of the less invasive methods and laser treatments in the office, and the traditional surgery is needed in case of serious or incurable cases. Simultaneously, the providers are working with more stringent budgets and increased responsibility for the outcomes, utilization, and overall treatment expenses. The regulatory demands and surgeon training requirements, as well as procurement schedules, have also come to play in the purchasing decisions.

The market now needs a more discriminatory and evidence-based method for decision-makers. Value is no longer determined by the performance of the devices; workflow influence, reimbursement conformity, patient throughput, and long-term service support also influence value. The local demand patterns are diverse depending on their access to healthcare and treatment pathways, and local strategy is important. Organizations and suppliers that strike a balance between innovation and cost, training, and operational productivity are more likely to be in a better position to exploit growth up to the forecast period.

Key Market Insights

• Glaucoma has a prevalence of more than 50% of its cases undiagnosed in the world, increasing the demand for screening.
• MIGS processes increased by 18% around the world in 2025 for elective recuperation.
• There was an increase of 14 outpatient ophthalmic surgeries, which boosted ASC glaucoma adoption.
• Now the patients aged 60+ constitute 62% of glaucoma treatment volumes.
• Asia Pacific Eye Clinic (urban) also implemented 11% surgical capacity.
• The laser glaucoma procedures enhanced throughput by 22% compared with OR scheduling.
• Minimally invasive platforms gained 9% of the hospital capital budgets.
• Approximately 70% of the cases of glaucoma diagnosed in adults are open-angle glaucoma.
• Pilots who monitored remotely decreased a missed glaucoma follow-up by 17.
• Training programs on the use of devices reduced the time taken by the surgeons by 26%.
• The emerging markets augmented the import of ophthalmology equipment 13% in the year 2025.
• Same-day glaucoma surgeries have topped over 40% of the chosen markets.
• Top eye centers were found to have 16 percent quicker MIGS patient conversion.
• There was an 8-percent increase in congenital glaucoma referrals with the increase in the neonatal screening.

Research Methodology

Scope & definitions

• Covers revenue for glaucoma therapeutic devices: drainage implants, MIGS devices, laser-based treatment systems, and related procedural hardware used in glaucoma management.
• Excludes pharmaceuticals, diagnostic-only devices, general ophthalmic consumables, and unrelated surgical equipment.
• Geography: global with regional/country splits; timeframe includes historical, base year, and forecast period stated in-report.
• Segmentation follows mutually exclusive rules by device type, surgery type, end user, disease type, and region. Data dictionary defines each field; double counting is removed across channels and bundled sales.

Evidence collection (primary + secondary)

• Primary research across OEMs, distributors, ophthalmologists, glaucoma surgeons, hospitals, ASCs, procurement heads, and channel partners.
• Secondary sources include company annual reports, investor filings, product literature, clinical publications, patent databases, WHO, FDA, EMA, and relevant regulators/standards bodies/industry associations specific to Global Glaucoma Therapeutics Devices Market (named in-report).
• Key claims are supported with verifiable sources and source-linked evidence within the report.

Triangulation & validation

• Market sizing uses bottom-up aggregation of company/device revenues and top-down modeling from ophthalmology procedure/equipment spending.
• Results are reconciled to financial disclosures where applicable.
• Conflicting-source resolution, outlier testing, interview back-checks, and analyst peer review control bias.

Presentation & auditability

• Transparent assumptions, formulas, and forecast drivers are documented.
• Tables/charts are source-tagged, version-controlled, and reproducible for audit-ready decision use.

Global Glaucoma Therapeutics Devices Market Drivers

Minimally invasive surgeries are transforming the priorities in the treatment of glaucoma.

Minimally invasive glaucoma surgeries are increasingly popular among healthcare facilities due to their conformance with the current aims of modern surgery, which are efficiency, accuracy, and rapid healing of patients. These solutions can usually fit into the current ophthalmic workflow and allow surgeons to operate on more cases without increasing the operating capacity. Such techniques that decrease the burden of postoperative care and enhance schedule flexibility are appreciated by hospitals and specialty centers as well.

Intelligent laser platforms are speeding up the uptake of outpatient care.

Developed laser platforms are on the rise, with providers updating glaucoma treatment with more rapid and resource-efficient treatment models. Most eye care facilities are increasing outpatient capacity and trying to find technologies that can reduce the complexity of procedures but still deliver clinical consistency. Newer systems that have better controls, integration of workflow, and simplified operation are more widely adopted in specialty practices and multisite networks.

The growing population of people of a certain age is putting a strain on scalable care.

The increasing aging population is posing a long-term challenge to the eye care systems to provide glaucoma treatment on a larger scale. Given the fact that the risk of glaucoma increases with age, providers are gearing up to treat more patients who would need continuous monitoring and prompt treatment. This requirement leans towards therapeutic equipment that can aid in standard work processes, reproducible results, and effective throughput throughout the hospital environment and clinics.

Global Glaucoma Therapeutics Devices Market Restraints

The market has a stubborn barrier in spite of the strong clinical need in the market. The high price of the premium device deters its adoption in cost-sensitive systems as uneven reimbursement decelerates the upgrade of the procedure. The switch of methods, delaying scale-up may often need training of the surgeons. Regulatory channels are long and vary from nation to nation. Capital budgets are also weighed in opposition to competing priorities in hospitals.

Global Glaucoma Therapeutics Devices Market Opportunities

It is generating significant prospects of high-tech surgical platforms with shortened recovery and enhanced workflow efficiency due to the increased need for earlier intervention on glaucoma. Growth in the number of outpatient eye care centers facilitates the sooner implementation of compact treatment systems that have reduced operating expenses. There is untapped potential in emerging markets due to the increased access to screening and the capacity of specialists.

How this market works end-to-end

1. Disease Detection
   Patients are identified through screening or symptom-led referral across glaucoma types.
2. Risk Stratification
   Clinicians assess pressure levels, progression risk, and medication response.
3. Therapy Escalation
   When drops fail or adherence is poor, procedural treatment becomes relevant.
4. Device Selection
   Providers compare drainage implants, MIGS devices, and laser systems based on case needs.
5. Site Choice
   Procedures shift between hospitals, ophthalmic clinics, and ASCs depending on complexity and economics.
6. Procurement Review
   Buyers compare price, service support, training, and supply continuity.
7. Procedure Delivery
   Devices are used in conventional or minimally invasive workflows.
8. Follow-Up Care
   Outcomes, pressure control, repeat procedures, and complications influence future demand.
9. Portfolio Refresh
   Providers reassess vendors as technology and reimbursement evolve.

Why this market matters now

The core issue is capacity planning under constraint. Demand for glaucoma care is rising while specialist time remains limited. Many systems still carry delayed care from earlier disruptions. That increases pressure for treatments that shorten procedure time, reduce recovery burden, or improve adherence versus medication-only pathways.

Capital budgets are also tighter. Buyers must justify every platform purchase with clear utilization logic. At the same time, supply chains remain more fragile than many assume. Concentrated manufacturing, freight volatility, and regulatory complexity can affect lead times.

Technology cycles add another layer. Some buyers overpay for innovation that does not fit local case volume. Others underinvest and lose referral share. The timing question matters as much as the product question.

What matters most when evaluating claims in this market

The decision lens

1. Define Boundary
   Confirm if you need device revenue, procedure demand, or full care pathway economics.
2. Map Use Cases
   Separate hospitals, clinics, and ASCs. Needs differ sharply.
3. Compare Options
   Benchmark MIGS, drainage, and laser pathways by case mix.
4. Stress Economics
   Model utilization, consumables, training time, maintenance, and reimbursement.
5. Test Exposure
   Check supplier concentration, regional dependence, and lead-time risk.
6. Validate Timing
   Watch budget cycles, policy shifts, and competitor adoption signals.
7. Build Scenarios
   Use base, upside, and disruption cases before committing capital.

The contrarian view

Many market estimates overstate opportunity by mixing device sales with procedure value. Some count both capital equipment and recurring accessories without clean boundaries. Others assume MIGS growth automatically displaces all legacy treatments. It does not.

Another common error is treating global demand as uniform. Reimbursement, surgeon preference, and site-of-care economics vary widely. A region with strong demand may still be unattractive if margins compress or approvals slow.

Finally, buyers often focus on headline CAGR and ignore installed-base inertia. Once a center trains staff and standardizes workflow, switching can be slower than expected.

Practical implications by stakeholder

Device Manufacturers

• Prioritize training-enabled adoption, not product launch alone.
• Build dual focus on premium and value segments.
• Reduce supply concentration risk.

Hospitals

• Tie purchases to throughput and referral retention.
• Compare OR use versus laser clinic models.
• Audit total ownership cost.

Ophthalmic Clinics

• Use niche specialization to win procedural volume.
• Evaluate compact systems with faster payback.

Ambulatory Surgical Centers

• Target efficient case selection.
• Negotiate service uptime commitments.

Investors

• Separate real recurring revenue from one-time installs.
• Test reimbursement sensitivity by region.

Distributors

• Win through training, inventory reliability, and local access support.

GLAUCOMA THERAPEUTICS DEVICES MARKET REPORT COVERAGE:

Global Glaucoma Therapeutics Devices Market Segmentation

Global Glaucoma Therapeutics Devices Market – By Device Type

• Introduction/Key Findings
• Drainage Devices (Glaucoma Drainage Implants)
• Minimally Invasive Glaucoma Surgery (MIGS) Devices
• Laser Devices
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Minimally invasive glaucoma surgery devices are leading with a 44% share due to the cataract-combined surgeries and faster recovery. Their safety profile is what is preferred to enable suppliers to maintain high pricing, surgeon-wide adoption, and repeat placement action in developed markets across the world now and even more so now.

Fortunately, minimally invasive glaucoma surgery devices are the fastest growing since the demand for outpatient care rises quicker and the training becomes more and more stable. It is projected that the market will keep improving for drainage implants by 31% and laser systems by almost 18% in the 2030 global markets, with good uptake trends in the near future.

Global Glaucoma Therapeutics Devices Market – By Surgery Type

• Introduction/Key Findings
• Minimally Invasive Glaucoma Surgery (MIGS)
• Conventional Glaucoma Surgery
• Laser Surgery
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Glaucoma Therapeutics Devices Market – By End User

• Introduction/Key Findings
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers (ASCs)
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Glaucoma Therapeutics Devices Market – By Disease Type

• Introduction/Key Findings
• Open-Angle Glaucoma
• Angle-Closure Glaucoma
• Normal-Tension Glaucoma
• Congenital Glaucoma
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Open-angle glaucoma has a 61% share, as it is more likely to be diagnosed, and the treatment outcomes are highly successful worldwide. Its repeated monitoring requirements have underpinned its sustained device demand in the hospitals, clinics, and ASCs around the globe today, which are steadily increasing patient bases every year in that regard.

Congenital glaucoma has the highest growth rate, although it has a 6% share, as the pediatric screening is better and referrals have increased at a higher rate all over the world. Procedures grow with earlier intervention, and specialist centers invest in precision equipment and training capacity within key markets this decade, soon.

Global Glaucoma Therapeutics Devices Market– Regional Analysis

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

The highest share of 38% is in North America, with the support of the reimbursement depth, advanced surgeons, and high uptake of premium devices. Revenues anchor with the United States, and with additional consistent replacement demand and innovation spending annually in the health systems today, steady growth momentum is present with a stable growth trend now.

The Asia Pacific is growing at the fastest rate of 27% share due to the increased rate of expansion of diagnosis and surgical capacity of aging populations. China, India, Japan, and Southeast Asia power procurement profits by clinic upgrades and broader access plans. In short, medium, and long term, it now rushes forward fast now and fast.

Latest Market News

• On Apr 12, 2026, iSTAR Medical said that it saw further commercial traction behind MINIject, with over 5,000 patients implanted around the world, and it still plans to submit its regulatory application to the U.S. in 2028. The news is an indicator of the continued confidence in supraciliary MIGS' demand and pipeline growth.
• Feb 20, 2026 Discussions of the American Glaucoma Society 2026 meeting on the new product pipeline New categories of investigational MIGS discussed at the meeting cover 3 major categories of devices and a variety of next-generation drainage technologies. The incident highlighted the increase in the intensity of R&D going into the 2026 planning cycle.
• Dec 05, 2025 U.S. market commentary: 4 new modalities of glaucoma treatments were available, including sustained-release implants with a profile of about 1-year and almost 3-year durations. The change is indicative of the increasing trend towards not relying on drop-dependent models of care.
• On Apr 24, 2025, iSTAR Medical reported 5-year STAR-GLOBAL data with MINIject having a sustained reduction of intraocular pressure of 38 percent and 83 percent with more than 20 percent reduction in pressure. Outcomes with long durations enhance the business argument towards standalone MIGS adoption.
• On Apr 21, 2025, Sight Sciences introduced the OMNI Edge Surgical System, with 21 µL viscoelastic capacity, and the product debuted on Apr 25-27, 2025. The introduction increases the competition in MIGS without implants.
• Mar 25, 2025 Three-year updates of the GEMINI study of the OMNI Surgical System revealed an average pressure reduction of 34% during year 1, and 74% of the patients were drug-free during year 3. The information is used in making claims of durability in interventional glaucoma management.
• Jan 14, 2025: Commentary of the NT-501 clinical trial reported stable intraocular pressure up to 24 months and a new study completion date of Dec 25, 2025. The innovation continued to focus on neuroprotection-based glaucoma innovation beyond the stay-pressure pressure control.
• On Apr 11, 2024, Glaukos finalized the deal to acquire some ophthalmology assets to enhance its surgical glaucoma business, which is part of a wider strategy surrounding interventional care and pipeline depth. The acquisition was preceded by previous integration moves and exposure to 2 key ophthalmic segments with multiple markets.

Key Players

1. Alcon Inc.
2. Johnson & Johnson Vision
3. Glaukos Corporation
4. Bausch + Lomb Corporation
5. AbbVie Inc.
6. Carl Zeiss Meditec AG
7. Topcon Corporation
8. Ellex Medical Lasers Ltd.
9. Iridex Corporation
10. Santen Pharmaceutical Co., Ltd.

Questions buyers ask before purchasing this report

Is this report useful if we only operate in one region?

Yes. A strong global report should still help a regional operator because it shows where technologies mature first, where pricing pressure begins, and which care models spread across borders. It also helps benchmark local assumptions against broader trends. The best use is to localize the global findings into your market access, reimbursement, and competitor context.

Does this market include drugs or only devices?

This scope is device-led. That matters because drug markets follow different economics, channels, and regulation. If you need a full glaucoma treatment strategy, devices should be assessed alongside medication adherence trends and procedural substitution risk. Clean boundaries prevent double counting and improve capital planning.

Can this report help with procurement decisions?

Yes, if it breaks demand by device type, site of care, and region. Procurement teams need more than growth forecasts. They need likely utilization, service expectations, vendor concentration risk, replacement cycles, and timing signals. Those factors often matter more than list price.

How do I judge whether MIGS demand is real?

Look for evidence tied to surgeon adoption, reimbursement support, patient selection, and site workflow fit. Demand claims based only on innovation buzz are weak. Real demand shows up in trained users, repeat purchasing, and integration into standard treatment pathways.

Why does end-user segmentation matter?

Hospitals, clinics, and ASCs buy for different reasons. Hospitals may focus on complex cases and broader service lines. Clinics may seek speed and differentiation. ASCs often optimize efficiency. A report that merges them can hide where real demand sits.

Can investors use this report?

Yes. Investors can use it to test whether revenue growth comes from sustainable procedure expansion, pricing, installed base upgrades, or one-time stocking. It also helps identify margin risk from competition or reimbursement shifts.

What risks are easiest to miss in this market?

Supplier concentration, regulatory delays, training bottlenecks, and overestimated utilization are common blind spots. Many buyers also miss how slowly clinician behavior changes after workflow standardization.

How often should buyers refresh this analysis?

In a changing medtech market, annual refresh is prudent. If you face a major capex decision, acquisition review, or regional expansion, update sooner. Conditions can change faster than planning cycles.